PhotonPharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PhotonPharma, Inc. - overview
Established
2018
Location
Fort Collins, CO, US
Primary Industry
Biotechnology
About
Founded in 2018 by Ray Goodrich, and based in Colorado, US, PhotonPharma, Inc. is a biopharmaceutical company engaged in the development of treatments and therapies for cancer. In August 2024, PhotonPharma, Inc. raised USD 2.
5 million in seed funding from various investors. As of September 2024, the company is being led by its CEO, Alan Rudolph. PhotonPharma Inc. is an immuno-oncology company focused on developing an autologous cell therapy platform for treating solid tumor cancers.
The company's technology stimulates a patient's immune system to target and destroy cancer cells. PhotonPharma's patented process inactivates the DNA/RNA of the patient's tumor cells while preserving the cells' tumor-specific antigen targets (neoantigens). This process allows the modified cells to be re-administered to the patient on the same day. The company intends to use the August 2024 funding to support the phase 1 clinical trial of its Innocell therapy for treating ovarian cancer.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.photonpharmaceuticals.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.